Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Parlane NA, Grage K, Mifune J, Basaraba RJ, Wedlock DN, Rehm BH, Buddle BM.

Clin Vaccine Immunol. 2012 Jan;19(1):37-44. doi: 10.1128/CVI.05505-11. Epub 2011 Nov 9.

2.

Bacterial polyester inclusions engineered to display vaccine candidate antigens for use as a novel class of safe and efficient vaccine delivery agents.

Parlane NA, Wedlock DN, Buddle BM, Rehm BH.

Appl Environ Microbiol. 2009 Dec;75(24):7739-44. doi: 10.1128/AEM.01965-09. Epub 2009 Oct 16.

3.

Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.

Parlane NA, Grage K, Lee JW, Buddle BM, Denis M, Rehm BH.

Appl Environ Microbiol. 2011 Dec;77(24):8516-22. doi: 10.1128/AEM.06420-11. Epub 2011 Oct 7.

4.

Novel particulate vaccines utilizing polyester nanoparticles (bio-beads) for protection against Mycobacterium bovis infection - a review.

Parlane NA, Rehm BH, Wedlock DN, Buddle BM.

Vet Immunol Immunopathol. 2014 Mar 15;158(1-2):8-13. doi: 10.1016/j.vetimm.2013.04.002. Epub 2013 Apr 30. Review.

PMID:
23707076
5.

Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.

Lu J, Wang C, Zhou Z, Zhang Y, Cao T, Shi C, Chen Z, Chen L, Cai C, Fan X.

Clin Dev Immunol. 2011;2011:617892. doi: 10.1155/2011/617892. Epub 2011 Feb 27.

6.

Comparison of BCG prime-DNA booster and rBCG regimens for protection against tuberculosis.

Tan K, Liang J, Teng X, Wang X, Zhang J, Yuan X, Fan X.

Hum Vaccin Immunother. 2014;10(2):391-8. doi: 10.4161/hv.26969. Epub 2013 Nov 5.

8.

Evaluation of protective efficacy conferred by a recombinant Mycobacterium bovis BCG expressing a fusion protein of Ag85A-ESAT-6.

Deng YH, He HY, Zhang BS.

J Microbiol Immunol Infect. 2014 Feb;47(1):48-56. doi: 10.1016/j.jmii.2012.11.005. Epub 2013 Jan 26.

9.
10.

Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+.

Pereira VB, Saraiva TD, Souza BM, Zurita-Turk M, Azevedo MS, De Castro CP, Mancha-Agresti P, Dos Santos JS, Santos AC, Faria AM, Leclercq S, Azevedo V, Miyoshi A.

Appl Microbiol Biotechnol. 2015 Feb;99(4):1817-26. doi: 10.1007/s00253-014-6285-3. Epub 2014 Dec 14.

PMID:
25503506
11.

Live attenuated Salmonella vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against Mycobacterium tuberculosis.

Juárez-Rodríguez MD, Yang J, Kader R, Alamuri P, Curtiss R 3rd, Clark-Curtiss JE.

Infect Immun. 2012 Feb;80(2):815-31. doi: 10.1128/IAI.05526-11. Epub 2011 Dec 5.

12.

Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.

Wang P, Wang L, Zhang W, Bai Y, Kang J, Hao Y, Luo T, Shi C, Xu Z.

Hum Vaccin Immunother. 2014;10(1):150-8. doi: 10.4161/hv.26171. Epub 2013 Aug 27.

13.

Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice.

Todoroff J, Lemaire MM, Fillee C, Jurion F, Renauld JC, Huygen K, Vanbever R.

PLoS One. 2013 May 10;8(5):e63344. doi: 10.1371/journal.pone.0063344. Print 2013.

15.

Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis.

Liang Y, Wu X, Zhang J, Xiao L, Yang Y, Bai X, Yu Q, Li Z, Bi L, Li N, Wu X.

FEMS Immunol Med Microbiol. 2012 Dec;66(3):419-26. doi: 10.1111/1574-695X.12008.

16.

Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis.

Pérez de Val B, Villarreal-Ramos B, Nofrarías M, López-Soria S, Romera N, Singh M, Abad FX, Xing Z, Vordermeier HM, Domingo M.

Clin Vaccine Immunol. 2012 Sep;19(9):1339-47. doi: 10.1128/CVI.00275-12. Epub 2012 Jul 3.

17.

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.

18.

Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.

Dou J, Wang Y, Yu F, Yang H, Wang J, He X, Xu W, Chen J, Hu K.

Int J Immunogenet. 2012 Apr;39(2):183-90. doi: 10.1111/j.1744-313X.2011.01066.x. Epub 2011 Dec 8.

PMID:
22152009
19.

Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

Romano M, Roupie V, Wang XM, Denis O, Jurion F, Adnet PY, Laali R, Huygen K.

Immunology. 2006 Jul;118(3):321-32.

20.

Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.

Xu Y, Zhu B, Wang Q, Chen J, Qie Y, Wang J, Wang H, Wang B, Wang H.

FEMS Immunol Med Microbiol. 2007 Dec;51(3):480-7. Epub 2007 Oct 4.

Supplemental Content

Support Center